• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of a novel lung adenocarcinoma treatment targeting autophagic cell death

Research Project

Project/Area Number 21K06691
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 47060:Clinical pharmacy-related
Research InstitutionUniversity of Miyazaki

Principal Investigator

Minami Kentaro  宮崎大学, 医学部, 薬剤師 (20735956)

Co-Investigator(Kenkyū-buntansha) 池田 龍二  宮崎大学, 医学部, 教授 (50398278)
Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2023: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2022: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2021: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywordsオートファジー / 肺腺癌 / 腫瘍抑制因子 / がん抑制遺伝子 / 癌治療
Outline of Research at the Start

我が国の肺癌の罹患率は高く、死亡数は依然として第1位である。この不良な治療成績を改善することが最大の課題である。我々はBHLHE41が肺腺癌において腫瘍抑制的に働くことを見出した。この肺腺癌における増殖抑制機構にオートファジーが関わっていることが示唆された。しかし、その詳細なメカニズムについてはまだわかっていない。本研究ではBHLHE41の解析を通じてがん治療への応用の可能性を探るために(1)BHLHE41によるオートファジー細胞死誘導機構(2)オートファジー細胞死以外の細胞死の関与(3)肺腺癌細胞におけるBHLHE41の発現制御の解析を行う。

Outline of Final Research Achievements

In this study, we aimed to clarify the mechanism by which BHLHE41 induces autophagic cell death. Expressed BHLHE41 decreased the expression of Bax, Bcl2, and BNIP3. Since the decreased expression of Bcl2 is involved in autophagy, it was suggested that the decreased expression of Bcl2 is involved in autophagic cell death induced by BHLHE41. Expression of BHLHE41 also decreased the expression of the ferroptosis inhibitor AIFM2 and induced ferroptosis. In addition to autophagic cell death, BHLHE41 is also thought to induce ferroptosis. Since autophagy is also associated with ferroptosis, we plan to analyze the detailed mechanism of autophagy in the future.

Academic Significance and Societal Importance of the Research Achievements

BHLHE41は肺腺癌において悪性化進展においてオートファジー細胞死を誘導し腫瘍抑制的に働くことを明らかにしている。
BHLHE41の発現時にオートファジーの抑制に関わるBcl2の発現減少することからオートファジー誘導に関わっていることが示唆された。また、同時期にフェロトーシスも起こっていることが明らかになった。このBHLHE41のオートファジー細胞死の誘導メカニズムが分かれば新規肺腺癌治療薬の開発に繋がることが考えられる。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • Research Products

    (13 results)

All 2024 2023 2022 2021

All Journal Article (5 results) (of which Int'l Joint Research: 2 results,  Peer Reviewed: 5 results,  Open Access: 5 results) Presentation (8 results)

  • [Journal Article] Approach to Functions of BHLHE41/DEC2 in Non-Small Lung Cancer Development2023

    • Author(s)
      Furukawa Tatsuhiko、Mimami Kentaro、Nagata Toshiyuki、Yamamoto Masatasu、Sato Masami、Tanimoto Akihide
    • Journal Title

      International Journal of Molecular Sciences

      Volume: 24 Issue: 14 Pages: 11731-11731

    • DOI

      10.3390/ijms241411731

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann-Pick disease type C treatment.2023

    • Author(s)
      Yamada Y, Fukaura-Nishizawa M, Nishiyama A, Ishii A, Kawata T, Shirakawa A, Tanaka M, Kondo Y, Takeo T, Nakagata N, Miwa T, Takeda H, Orita Y, Motoyama K, Higashi T, Arima H, Seki T, Kurauchi Y, Katsuki H, Higaki K, Minami K, Yoshikawa N, Ikeda R, Matsuo M, Irie T, Ishitsuka Y.
    • Journal Title

      Clin Transl Med.

      Volume: 13 Issue: 8

    • DOI

      10.1002/ctm2.1350

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Development of a highly sensitive method for the quantitative analysis of modified nucleosides using UHPLC-UniSpray-MS/MS2021

    • Author(s)
      Kogaki T, Ohshio I, Ura H, Iyama S, Kitae K, Morie T, Fujii S, Sato S, Nagata T, Takeda AH, Aoki M, Ueda K, Minami K, Yamamoto M, Kawahara K, Furukawa T, Sato M, Ueda Y, Jingushi K, Tozuka Z, Saigusa D, Hase H, Tsujikawa K.
    • Journal Title

      J Pharm Biomed Anal.

      Volume: 197 Pages: 113943-113954

    • DOI

      10.1016/j.jpba.2021.113943

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] ALKBH4 promotes tumourigenesis with a poor prognosis in non-small-cell lung cancer.2021

    • Author(s)
      Kentaro Jingushi,Masaya Aoki,Kazuhiro Ueda,Takahiro Kogaki,Masaya Tanimoto,Yuya Monoe,Masayuki Ando,Takuya Matsumoto,Kentaro Minami,Yuko Ueda,Kaori Kitae,Hiroaki Hase,Toshiyuki Nagata,Aya Harada-Takeda,Masatatsu Yamamoto,Kohichi Kawahara,Kazuhiro Tabata,Tatsuhiko Furukawa,Masami Sato,Kazutake Tsujikawa
    • Journal Title

      Scientific reports

      Volume: 11 Issue: 1 Pages: 8677-8677

    • DOI

      10.1038/s41598-021-87763-1

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] BHLHE41/DEC2 Expression Induces Autophagic Cell Death in Lung Cancer Cells and Is Associated with Favorable Prognosis for Patients with Lung Adenocarcinoma.2021

    • Author(s)
      Toshiyuki Nagata, Kentaro Minami, Masatatsu Yamamoto, Tsubasa Hiraki, Masashi Idogawa, Katsumi Fujimoto, Shun Kageyama, Kazuhiro Tabata, Kohichi Kawahara, Kazuhiro Ueda, Ryuji Ikeda, Yukio Kato, Masaaki Komatsu, Akihide Tanimoto, Tatsuhiko Furukawa, Masami Sato
    • Journal Title

      International journal of molecular sciences

      Volume: 22 Issue: 21 Pages: 11509-11509

    • DOI

      10.3390/ijms222111509

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] 病院薬剤師が挑む新規肺腺癌治療薬の開発2024

    • Author(s)
      南謙太朗、池田龍二
    • Organizer
      日本薬学会第144年会
    • Related Report
      2023 Annual Research Report
  • [Presentation] Ribonucleotide reductaseはgemcitabine耐性膵癌細胞の耐性克服の標的となる2023

    • Author(s)
      南謙太朗、山本雅達、河原康一、古川龍彦、池田龍二
    • Organizer
      第40回日本薬学会九州山口支部大会
    • Related Report
      2023 Annual Research Report
  • [Presentation] FMNL1の発現は悪性膠芽腫の運動性と浸潤性に関わる予後不良因子である2022

    • Author(s)
      古川龍彦、河原康一、南謙太朗
    • Organizer
      第26回 日本がん分子標的治療学会学術集会
    • Related Report
      2022 Research-status Report
  • [Presentation] オートファジ―誘導遺伝子BHLHE41の抗腫瘍活性2022

    • Author(s)
      古川龍彦、南 謙太朗、永田俊之、山本雅達、河原康一、蔭山 俊、小松勝明、佐藤雅美
    • Organizer
      第8回がんと代謝研究会
    • Related Report
      2022 Research-status Report
  • [Presentation] Integrin β5 inhibitor can suppress gastric cancer cell invasiveness through Integrinβ5-FARP1-CDC42 cascade2022

    • Author(s)
      古川龍彦、南謙太朗、河原康一、山本雅達
    • Organizer
      第95回 日本薬理学会年会
    • Related Report
      2021 Research-status Report
  • [Presentation] FARP1はインテグリンαvβ5によるCDC42の活性化に関わり、進行胃がんの予後に関わる2021

    • Author(s)
      古川龍彦、河原康一、南謙太朗
    • Organizer
      第25回 日本がん分子標的治療学会学術集会
    • Related Report
      2021 Research-status Report
  • [Presentation] オートファジー誘導分子DEC2 によるアポトーシス誘導因子BAXの発現抑制2021

    • Author(s)
      坂本洸大、山本雅達、南謙太朗、古川龍彦、河原康一、武井孝行、吉田昌弘
    • Organizer
      第58回 化学関連支部合同九州大会
    • Related Report
      2021 Research-status Report
  • [Presentation] FARP1 binds with integrinavb5 and FARP1 expression is correlate to poor prognoses of advanced gastric cancer patients2021

    • Author(s)
      古川龍彦、南 謙太朗、山本雅達、河原康一
    • Organizer
      第80回 日本癌学会学術総会
    • Related Report
      2021 Research-status Report

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi